Nanotechnology and Nanorobotics in Cancer Treatment

Abstract

Cancer, a complex and devastating disease, continues to plague humanity. There have been great advancements achieved in conventional treatments such as chemotherapy and radiation; however, these treatments frequently come with serious adverse effects and limited efficacy against certain types of tumors. In the relentless pursuit of more targeted and effective therapies, nanorobotics has emerged as a promising frontier. This article explores the potential of nanorobots in revolutionizing cancer treatment, drawing upon recent research and highlighting the key findings that underscore their transformative potential. Cancer treatment is currently limited by systemic toxicity and a lack of precise targeting. Nanorobots, nanoscale devices capable of performing specific tasks, offer a novel approach to overcome these limitations. This article reviews the potential applications of nanorobots in cancer treatment, including targeted drug delivery, tumor ablation, and early detection. Nanorobots can travel through the bloodstream, detect cancer cells, and deliver medicine directly to tumors, reducing harm to healthy tissues. They can also help track how well a treatment is working in real-time and detect cancer recurrence at an early stage. Although there are still challenges like compatibility with the body, large-scale production, and regulatory approval, progress in nanotechnology is bringing nanorobots closer to becoming an important part of future cancer treatment.

Keywords

Introduction

As a miniature structure, nanorobots are capable of executing predetermined missions and bear stark differences to their macroscale robotic counterparts. The primary challenges in the development of nanorobots or nanomechanical components lie in their construction and control. These devices operate within a microenvironment that exhibits physical characteristics distinct from those encountered by conventional components. The composition and structure of nanorobots are not uniform and can vary depending on their intended function and the materials and technologies utilized in their creation. The field of nanorobotics is an ever-evolving one, with ongoing advancements and breakthroughs. In this regard, we have presented a general outline of some of the crucial components and structures commonly found in nanorobots  and provided a summarization of typical examples of medical nanorobots  based on the study by Suhail et al.  Currently, most nanorobot experiments are conducted under conditions akin to those found in human microenvironments. To ensure that nanorobots can effectively eliminate cancer cells within the human body, scientists have set stringent standards for their fundamental design elements. It is noteworthy that medical nanorobots are still in the nascent stages of development and are yet to be widely implemented in medical treatments. The specific composition and structure of these devices may greatly vary based on their intended application and the necessary requirements for safety, efficacy, and scalability.

As cancer continues to take a toll on human beings worldwide, a more advanced and complex treatment method is nothing but, the need of the hour. Taking such a concept into consideration, the proper interpretation of nanoscience and the right use of nanomaterial could be the way forward. Nanomaterial-based therapeutics are believed to have numerous merits over old-school treatments such as Radiation Therapy, Chemotherapy, and so on, including their bioavailability, responses of cancerous cells on treatments, and reduction in side effects among patients. Based on the physiology of the abnormal state and anatomical characteristics of solid tumor tissues, nanomaterial could probably take advantage of the enhanced permeability and retention effect, which could accumulate and penetrate the affected cells. Other properties like its size, which is capable of moving away from the fixed macrophages and of resisting rapid leakage into the tiny capillaries, its surface characteristics, and passive and active targeting of tumors, are some of the vital properties of nanomaterial in cancer treatment (especially for drug delivery and further mechanisms). Parts of DNA and RNA, silk fabrications, and liposomes, are engineered into nanomaterial and hence used for delivering drugs, and other therapies. Certain inorganic nanomaterials are combined with Cancer photothermal therapies, which show us how inorganic nanoparticles will be useful in treating Cancer.

Concerning the work done by Douglas et al., we can have a glance at the construction of nanobots, made using DNA strands. It is known that the software used for the construction of nanobots was a software called “Cadnano,” which was an open-source programmable software. DNA Origami, a technique of making tiny components of DNA, was used to create these nanobots. A part of the DNA was cut into the desired small scale, as strands, and then, these tiny strands were attached to make a long and desired strand of essential dimensions.As in the case of DNA stranding, the desired shape and size are obtained when the two strands, interact with each other among the complementary base pairs. These bots consist of two halves which are openable and closable, as directed by the operator. These two halves are not separate as they are connected by a molecular hinge.They are bound together by laches or molecular locks made of DNA double helixes. The aptamers are attached outside. The payload, which carries the drugs and pharmaceuticals secured by molecular anchors, as mentioned earlier, is placed inside the nanobots. The aptamers hold the payloads inside the nanobots tightly and once the target is obtained, it opens itself and deposits the payload on the targetshows the design and construction of the nanobot.

APPLICATIONS

1. Targeted Drug Delivery: Nanoparticles (like liposomes, micelles, and polymers) encapsulate chemotherapy drugs, protecting them from degradation and preventing non-specific accumulation in healthy tissues.
2. ?Enhanced Permeability and Retention (EPR) Effect (Passive Targeting): Due to leaky tumor blood vessels and poor lymphatic drainage, nanoparticles naturally accumulate in tumor tissue more than in normal tissue, concentrating the drug at the site of cancer.
3. ?Active Targeting: Nanoparticles are functionalized (coated) with ligands, antibodies, or peptides that specifically bind to receptors (biomarkers) overexpressed on the surface of cancer cells, ensuring precise delivery.
4. ?Minimizing Systemic Toxicity: By delivering the maximum therapeutic dose directly to the tumor site, nanoparticles significantly reduce the concentration of the drug in the rest of the body, thereby lowering severe side effects.
5. ?Overcoming Multidrug Resistance  (MDR): Nanocarriers can bypass cellular mechanisms that cause drug resistance, such as efflux pumps, by delivering the drug directly into the cancer cell's cytoplasm.
6. ?Combination Therapy Delivery: Nanoparticles can be loaded with multiple agents (e.g., chemotherapy and gene therapy agents) to achieve a synergistic killing effect on cancer cells.
7. ?Photothermal Therapy (PTT): Nanomaterials like gold nanoshells or carbon nanotubes absorb near-infrared light and convert it into heat, selectively ablating (destroying) the cancer cells they have accumulated in.
8. ?Photodynamic Therapy (PDT): Nanoparticles carry photosensitizers that, when activated by a specific wavelength of light, produce reactive oxygen species (ROS) to kill tumor cells.
9. ?Magnetic Hyperthermia: Magnetic nanoparticles are guided to the tumor and heated using an external alternating magnetic field, causing local hyperthermia to kill the cancer cells.
10. ?Enhanced Diagnostic Imaging: Nanoparticles loaded with both a therapeutic agent and an imaging contrast agent (e.g., Quantum Dots, MRI contrast agents) allow for simultaneous diagnosis, treatment, and real-time monitoring of drug distribution.
11. ?Gene Therapy Delivery: Nanocarriers safely and effectively transport nucleic acids  into cancer cells to correct or silence defective genes that contribute to tumor growth
12. ?Immunotherapy Enhancement: Nanoparticles are used to deliver antigens, adjuvants, or checkpoint inhibitors to immune cells, boosting the body's own immune response against the tumor.
13. ?Detection of Biomarkers: Nanosensors and quantum dots can rapidly and accurately detect ultra-low concentrations of cancer-specific biomarkers in blood, enabling earlier and more sensitive cancer diagnosis.

Nanorobotic pharmaceutical Applications

1. ?Autonomous Targeted Ablation: Nanorobots are envisioned to autonomously navigate to a tumor and execute targeted destruction using mechanical, thermal, or chemical methods.
2. ?Minimally Invasive Nanoscale Surgery: Nanorobots could perform complex tasks like dissecting tissue, clearing blockages, or manipulating cells at a subcellular level with unprecedented precision.
3. ?Real-Time Cellular Monitoring: Nanobots equipped with biosensors can monitor the tumor microenvironment (e.g., pH levels, oxygen tension, enzyme activity) and release a drug payload only when specific cancer conditions are met (stimuli-responsive release).
4. ?Clot Dissolution and Vascular Access: Nanorobots may be used to clear blood clots obstructing blood flow to a tumor after therapy or to create pathways for therapeutic access.
5. ?Precision Drug Dosing and Release: Nanorobots offer superior control over the drug release kinetics compared to simple nanoparticles, ensuring optimal therapeutic concentration exactly where and when it is needed.
6. ?Cancer Cell Isolation: Magnetic nanorobots could be guided to capture and isolate rare circulating tumor cells (CTCs) from the bloodstream for advanced diagnostic analysis.

CONCLUSION

The main target of writing this review was to provide an outline of the technological development of nanotechnology in medicine by making a nanorobot and introducing it in the medication of cancer as a new mode of drug delivery. Cancer is described as a collection of diseases characterised by the unregulated development and spread of malignant cells in the body, and the number of people diagnosed every year keeps adding up. Cancer treatment is most likely the driving force behind the creation of nanorobotics;

It can be auspiciously treated using existing medical technology and therapeutic instruments, with the major help of nanorobotics. To decide the prognosis and chances of survival in a cancer patient, consider the following factors: better prognosis can be achieved if the evolution of the disease is time-dependent and a timely diagnosis is made.

Another important aspect is to reduce the side effects of chemotherapy on the patients by forming efficient targeted drug delivery systems. Programmable nanorobotic devices working at the cellular and molecular level would help doctors to carry out precise treatment.

In addition to resolving gross cellular insults caused by non-reversible mechanisms or to the biological tissues stored cryogenically, mechanically reversing the process of atherosclerosis, enhancing the immune system, replacing or re-writing the DNA sequences in cells at will, improving total respiratory capacity, and achieving near-instant homeostasis, medically these nanorobots have been put forward for use in various branches of dentistry, research in pharmaceuticals, and aid and abet clinical diagnosis.

When nanomechanics becomes obtainable, the ideal goal of physicians, medical personnel, and every healer throughout known records would be realized. Microscale robots with programmable and controllable nanoscale components produced with nanometre accuracy would enable medical physicians to perform at the cellular and molecular levels to heal and carry out rehabilitating surgeries.

Nanomedical doctors of the 21st century will continue to make effective use of the body's inherent therapeutic capacities and homeostatic systems, since, all else being equal, treatments that intervene the least are the best.

In conclusion, nanoparticles and especially nanorobotics are not just incremental improvements; they represent a paradigm shift in oncology, offering the potential for more effective, patient-friendly, and precise cancer care that can increase survival rates and drastically improve the quality of life for patients. The future will involve a greater integration of these nanotechnologies with fields like Artificial Intelligence (AI) to design and control the next generation of "smart" nanomedicine systems

REFERENCES

1. Siegel, R. L., Miller, K. D., Wagle, N. S. & Jemal, A. Cancer statistics, 2023. CA-Cancer J. Clin. 73, 17–48 (2023).
2. Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA-Cancer J. Clin. 71, 209–249 (2021).
3. Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2019. CA-Cancer J. Clin 69, 7–34 (2019).
4. McGuire, S. Geneva, Switzerland: world health organization, international agency for research on cancer, WHO press, 2015. Adv. Nutr. 7, 418–419 (2016).
5. Wells, J. C. et al. An analysis of contemporary oncology randomized clinical trials from low/middle-income vs high-income countries. JAMA Oncol 7, 379–385 (2021).
6. Pramesh, C. S. et al. Priorities for cancer research in low- and middle-income countries: a global perspective. Nat. Med. 28, 649–657 (2022).
7. Slomski, A. Global cancer burden grew from 2010 to 2019. Jama 327, 804 (2022).
8. Harbeck, N. et al. Breast cancer. Nat. Rev. Dis. Primers. 5, 66 (2019).
9. Cives, M. &Strosberg, J. R. Gastroenteropancreatic Neuroendocrine Tumors. CA: Cancer J. Clin. 68, 471–487 (2018).
10. Cheng, L. et al. Testicular cancer. Nat. Rev. Dis. Primers. 4, 29 (2018).
11. Crosbie, E. J. et al. Endometrial cancer. Lancet 399, 1412–1428 (2022).
12. Leon-Ferre, R. A. & Goetz, M. P. Advances in systemic therapies for triple negative breast cancer. BMJ 381, e071674 (2023).
13. Chainitikun, S. et al. Update on systemic treatment for newly diagnosed inflammatory breast cancer. J. Adv. Res. 29, 1–12 (2021).
14. Turchan, W. T., Pitroda, S. P. & Weichselbaum, R. R. Radiotherapy and immunotherapy combinations in the treatment of patients with metastatic disease: current status and future focus. Clin. Cancer Res. 27, 5188–5194 (2021)
15. De Ruysscher, D. et al. Radiotherapy toxicity. Nat. Rev. Dis. Primers. 5, 13 (2019).